Dyne Therapeutics, Inc. (DYN): Cash & Equivalents
$893.37M
As of 2025-12-31
$676.11M
As of 2026-06-30
+73.1%
3-year compound annual growth
+24.3%
5-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $893.37M | +105.2% | 2026-03-02, Balance as of period end |
| 2024-12-31 | $435.45M | +258.0% | 2026-03-02, Balance as of period end |
| 2023-12-31 | $121.63M | -29.3% | 2025-02-27, Balance as of period end |
| 2022-12-31 | $172.15M | -14.3% | 2024-03-05, Balance as of period end |
| 2021-12-31 | $200.82M | -33.2% | 2023-03-02, Balance as of period end |
| 2020-12-31 | $300.85M | n/m | 2022-03-10, Balance as of period end |
| 2019-12-31 | $14.63M | n/a | 2021-03-04, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Dyne Therapeutics, Inc. (DYN) | 2025-12-31 | $893.37M | +105.2% |
| Indivior Pharmaceuticals, Inc. (INDV) | 2025-12-31 | $195.00M | -38.9% |
| Zai Lab Ltd (ZLAB) | 2025-12-31 | $679.57M | +51.1% |
| Arcus Biosciences, Inc. (RCUS) | 2025-12-31 | $222.00M | +48.0% |
| Madrigal Pharmaceuticals, Inc. (MDGL) | 2025-12-31 | $198.69M | +98.7% |
| Pacira BioSciences, Inc. (PCRX) | 2025-12-31 | $158.54M | -42.7% |
| IDEAYA Biosciences, Inc. (IDYA) | 2025-12-31 | $112.83M | +33.7% |
| Harmony Biosciences Holdings, Inc. (HRMY) | 2025-12-31 | $752.50M | +66.1% |
| Agios Pharmaceuticals, Inc. (AGIO) | 2025-12-31 | $89.13M | +16.9% |
Compare DYN, INDV, ZLAB, RCUS side by side · Screen every company in Pharmaceutical Preparations ↗